Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Immunology/Infectious Diseases | Dermatology/Plastic Surgery
Clinical Trials: Hereditary Angioedema
A listing of clinical trials currently looking for volunteers to enroll in Hereditary Angioedema studies. Click on the closest city to find more detailed information on a research study in your area.
Arizona
Scottsdale : Allergy, Asthma & Immunology, Assoc, Ltd.
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Arkansas
Little Rock : Little Rock Allergry and Asthma Clinical Research Center
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
California
Bell Gardens : Sunrise Clinical Research
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Granada Hills : Allergy and Asthma Institute of the Valley
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Granada Hills : Allergy & Asthma Institute of the Valley
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Los Angeles : UCLA Department of Medicine Division of Clinical Immunology, David Geffen School of Medicine
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Los Angeles : Unidversity of California, Los Angeles David Geffen School of Medicine
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
View More »
Orange : 705 West LaVeta
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Walnut Creek : Allergy & Asthma Clinical Research Inc.
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Colorado
Colorado Springs : Asthma and Allergy Associates, P.C.
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Colorodo Springs : Associate, Asthma & Allergy Associates, P.C.
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Connecticut
Waterbury : Center for Allergy, Asthma & Immunology
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Florida
Tampa : University of South Florida
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Tampa : USF Asthma, Allergy and Immunology Clinical Research Unit
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Tampa : USF Asthma, Allergy and Immunology Clinical Research Unit
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Tampa : University of South Florida Asthma
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Georgia
Atlanta : Family Allergy and Asthma Center
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Columbus : Brookstone Clinical Research Center
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Illinois
Chicago : University Consultants in Allergry and Immunology
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Indiana
Evansville : Deaconess Clinic Downtown
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Muncie : Muncie Allergy Ctr
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Kansas
Overland Park : Kansas City Allergy and Asthma Associates
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Maryland
Chevy Chase : Institute for Asthma and Allergy, PC
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Chevy Chase : Institute for Asthma and Allergy
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Chevy Chase : Institute for Asthma and Allergy, P.C.
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Chevy Chase : Institute for Asthma and Allergy, P.C.
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Massachusetts
Boston : Boston Children's Hospital
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Chestnut Hill : Brigham and Women's Hospital
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Michigan
Ann Arbor : University of Michigan Health System Allergy Specialty Clinic
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Clinton Township : Asthma and Allergy Institute of Michigan
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Missouri
St. Louis : Asthma & Allergy Center - Washington University School of Medicine
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
St. Louis : Saint Louis University School of Medicine
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
St. Louis : Washington University School of Medicine
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Nevada
Reno : University of Nevada School of Medicine - Department of Pediatrics
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
New Jersey
Iselin : Allergy Treatment Center of New Jersey
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
New York
Mineola : Winthrop University Hospital Clinical Trials Center
HAE - Patients diagnosed with Acute Hereditary Angioedema
View More »
Bronx :
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Mineola : Winthrop University Hospital
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
North Syracuse : Medical Research Associates of CNY
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
North Carolina
Ashville : Allergy Partners of Western North Carolina
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Sanford : Specialty Medical Clinic And Research Center
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Ohio
Cincinnati : University of Cincinnati Physicians, Inc.
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Cincinnati : Department of Internal Medicine, University of Cincinnati -MSB
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Columbus : Optimed Research, LTD
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Columbus : Optimed Research, LTD
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Toledo : Reynolds Clinic
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Oklahoma
Tulsa : Allergy Clinic of the Tulsa, Inc.
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Oregon
Eugene : Allergy and Asthma Research Group
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Lake Oswego : Allergy, Asthma and Dermatoligy Research Center, LLC
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Lake Oswego : Baker Allergy, Asthma and Dermatology Research Center, LLC
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Pennsylvania
Hershey : Pennsylvania State- Milton S. Hershey Medical Center
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Hershey : Penn State University - Penn State Milton S. Hershey Medical Center
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Pittsburgh : Children's Hospital of Pittsburgh of UPMC
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Texas
Dallas : AARA Research Center
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Dallas : AARA Research Center
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Dallas : AARA Research Center
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Dallas : AARA Research Center
Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema
Dallas : AARA Research Center
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
View More »
Irving : Allergy, Asthma & Immunology Clinic, P.A.
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
San Antonio : Allergy and Asthma Research Center
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Utah
Salt Lake City : University of Utah, Department of Dermatology
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Virginia
Norfolk : Children's Hospital of the King's Daughters
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Virginia Beach :
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Washington
823 West Seventh Avenue : MaryCliff Allergy Specialists
Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
Spokane : Marycliff Allergy Specialists
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
Spokane : Marycliff Allergy Specialists
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Tacoma : Puget Sound Allergy, Asthma and Immunology
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema
Bulgaria
Sofia : UMHAT "Tsaritsa Yoanna - ISUL"; Clinic of Ear-Nose-Throat Diseases
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Germany
Berlin : Charité Hospital
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Essen : ViroPharma Investigational Site
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
Munich : Klinikum Rechts der Isar, Technical University Munich
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Hungary
Budapest : Semmelweis University Faculty of Medicine, III Department of Internal Medicine
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Israel
Haifa : Bnei Zion Hospital
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Tel Hashomer : Sheba Medical Center
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Tel-Aviv : Souraski Medical Center
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Italy
Milan : Ospedale Luigi Sacco, Azienda Ospedaliera - Polo Universitario II Divisione di Medicina Interna
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Milan : Hospital Luigi Sacco
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Macedonia, The Former Yugoslav Republic of
Skopje : P.H.U. Clinic for Dermatology, Medical University Skopje, Unit of Allergology and Clinical Immunology
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Netherlands
Poland
Krakow : Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Klinik Chorób Wewnętrznych, Poradnia Alergologiczna
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Krakow : Pediatric Hospital
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Lublin : Pediatric Hospital
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Romania
Targu Mures : Mures County Clinical Hospital
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Târgu-Mureş : Spitalul Clinic Judeţean Mureş Secţia Clinică Medicină Internă, Compartimentul de Alergologie şi Imunologie
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Serbia
Belgrade : Clinic for Immunology and Allergology
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Sweden
Danderyd : Various sites in Austria, France, Germany, Italy, Spain, Sweden and in the UK are participating in this Patient Registry. Recruiting countries are now Austria, Germany, France, Spain, Sweden, UK, Italy & Greece
Firazyr® Patient Registry Protocol
